Regulatory and translational hurdles GLP-1R-targeted nanomedicines face complex regulatory and translational challenges, primarily due to their interdisciplinary nature and structural complexity [546]

Heres an overview of the most popular GLP-1 medications and their key features: Semaglutide (Brand names: Ozempic, Wegovy, Rybelsus Features: Once-weekly injection (Ozempic, Wegovy) or daily oral tablet (Rybelsus) Approved for type 2 diabetes (Ozempic, Rybelsus) and weight management (Wegovy) Benefits: Significant weight loss Improved glycemic control Cardiovascular benefits Liraglutide (Brand names: Victoza, Saxenda) Features: Daily injection Victoza approved for type 2 diabetes, Saxenda for weight management Benefits: Moderate weight loss Improved blood sugar control Cardiovascular benefits Dulaglutide (Brand name: Trulicity) Features: Once-weekly injection Approved for type 2 diabetes Benefits: Improved glycemic control Moderate weight loss Cardiovascular benefits Tirzepatide (Brand name: Mounjaro) Features: Once-weekly injection Approved for type 2 diabetes, under review for weight management Dual GIP and GLP-1 receptor agonist Benefits: Significant weight loss Improved glycemic control Potential cardiovascular benefits Key differences: Efficacy: Semaglutide and tirzepatide generally show the most significant weight loss and glycemic control improvements

It mainly activates the GIP receptor strongly but only partly activates the GLP-1 receptor, and it prefers certain signaling pathways over others
effects are greater when part of a healthy lifestyle
Slower digestion can cause constipation
or a very rapid heartbeat